Clinical Trials
21
Active:14
Completed:5
Trial Phases
3 Phases
Phase 1:18
Phase 2:2
Not Applicable:1
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (21 trials with phase data)• Click on a phase to view related trials
Phase 1
18 (85.7%)Phase 2
2 (9.5%)Not Applicable
1 (4.8%)An Open-label, Dose-Escalation and Dose-Expansion Study of GB3226 in Patients With Relapsed/Refractory Acute Myeloid Leukemia
Not Applicable
Not yet recruiting
- Conditions
- Relapsed/Refractory Acute Myeloid Leukemia (AML)
- Interventions
- Drug: GB3226
- First Posted Date
- 2025-07-24
- Last Posted Date
- 2025-07-24
- Lead Sponsor
- Galecto Biotech AB
- Target Recruit Count
- 184
- Registration Number
- NCT07084584
A Study to Compare Pharmacokinetics of GB1211
- First Posted Date
- 2023-02-28
- Last Posted Date
- 2023-09-01
- Lead Sponsor
- Galecto Biotech AB
- Target Recruit Count
- 13
- Registration Number
- NCT05747573
- Locations
- 🇳🇱
QPS Netherlands BV, Groningen, Netherlands
A Study to Investigate the Safety and Efficacy of GB1211 (a Galectin-3 Inhibitor) in Combination With Atezolizumab in Patients With Non-Small Cell Lung Cancer (NSCLC).
Phase 1
Active, not recruiting
- Conditions
- Non-Small Cell Lung Cancer
- Interventions
- First Posted Date
- 2022-02-15
- Last Posted Date
- 2024-04-12
- Lead Sponsor
- Galecto Biotech AB
- Target Recruit Count
- 88
- Registration Number
- NCT05240131
- Locations
- 🇫🇷
Centre Georges Grancois Leclerc, Dijon, France
🇫🇷CHRU, Tours, France
🇵🇱Samodzielny Publiczny Zespol Gruzlicy I Chorob Pluc, Olsztyn, Poland
A Single and Repeat Dose Trial in Participants With Hepatic Impairment
- First Posted Date
- 2021-08-17
- Last Posted Date
- 2023-05-11
- Lead Sponsor
- Galecto Biotech AB
- Target Recruit Count
- 54
- Registration Number
- NCT05009680
- Locations
- 🇧🇬
COAMC Medical, Sofia, Bulgaria
🇧🇬Gastroenterology Clinic, Lozenets district, Sofia, Bulgaria
🇧🇬Diagnostic-Advisory center 'ALEKSANDROVSKA" Ltd, Sofia, Bulgaria
A Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Oral GB2064 in Participants With Myelofibrosis
- First Posted Date
- 2020-12-22
- Last Posted Date
- 2024-04-03
- Lead Sponsor
- Galecto Biotech AB
- Target Recruit Count
- 21
- Registration Number
- NCT04679870
- Locations
- 🇺🇸
MD Andersson Cancer Hospital, Houston, Texas, United States
🇦🇺Woden Dermatology, Canberra, Australia
🇩🇪Heinrich-Heine-University Dusseldorf, Düsseldorf, Germany
- Prev
- 1
- 2
- Next
News
No news found